The REAP consortium (including CMPBME) received EU grant to reveal drug tolerant persister cells in breast cancer both in vitro and in vivo in a mouse model using contrast enhanced multimodal optical imaging. We are proud too to share our first peer reviewed perspective article describing the general architecture of the project and the expected impact of REAP on the community.
